Drug Landscape ›
MOXIFLOXACIN ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 18,532
Most-reported reactions
Off Label Use — 2,257 reports (12.18%) Dyspnoea — 2,084 reports (11.25%) Drug Ineffective — 1,993 reports (10.75%) Drug Hypersensitivity — 1,931 reports (10.42%) Pneumonia — 1,925 reports (10.39%) Asthma — 1,901 reports (10.26%) Vomiting — 1,768 reports (9.54%) Pain — 1,611 reports (8.69%) Rash — 1,539 reports (8.3%) Wheezing — 1,523 reports (8.22%)
Source database →
MOXIFLOXACIN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is MOXIFLOXACIN approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for MOXIFLOXACIN in United States?
Marketing authorisation holder not available in our data.